| P2093 | author name string | Ralf Paschke | |
| | Peter Wiedemann | |
| | Katja Kühn | |
| | Claudia Jochmann | |
| | Florian Gerhard Wuthe | |
| P2860 | cites work | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 |
| | Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 |
| | Effects of intensive glucose lowering in type 2 diabetes | Q29547736 |
| | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 |
| | Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 |
| | Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 |
| | Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. | Q30969875 |
| | Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. | Q33305306 |
| | Diabetic retinopathy: Early diagnosis and effective treatment | Q33534657 |
| | Standards of medical care in diabetes--2010. | Q33554238 |
| | The outpatient care of diabetics. An analysis of the local compulsory medical insurance data from Dortmund | Q36763212 |
| | Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complicat | Q37127488 |
| | Diabetes: from phenotypes to genotypes. | Q41433026 |
| | Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy | Q42164528 |
| | Association of ocular disease and mortality in a diabetic population | Q44186257 |
| | Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 |
| | Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). | Q45014719 |
| | Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial | Q46341489 |
| | Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials | Q46341499 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | The 14-year incidence of visual loss in a diabetic population | Q47971799 |
| | Incidence of blindness in southern Germany due to glaucoma and degenerative conditions | Q48615358 |
| | Intensive glycemic control in the ACCORD and ADVANCE trials | Q53654194 |
| | Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials | Q59624463 |
| | The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years | Q70330516 |
| | Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study | Q72401492 |
| | Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group | Q73842153 |
| | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group | Q77223580 |
| | Relation of glycemic control to diabetic complications and health outcomes | Q77671391 |
| | [Adherence to medical treatment] | Q79364118 |
| | Genetics of diabetic retinopathy | Q79991658 |
| | [Prevalence of diabetic retinopathy. Check-up program of a public health insurance company in Germany 2002-2004] | Q80213101 |
| P433 | issue | 11 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | photobiomodulation | Q1872556 |
| | type 2 diabetes | Q3025883 |
| P304 | page(s) | 772-778 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Medizinische Klinik | Q11776847 |
| P1476 | title | Comparison of risk factors and guideline oriented prevention and therapy of diabetic retinopathy between type 2 diabetes patients undergoing laser therapy and type 2 diabetes outpatients | |
| P478 | volume | 105 | |